CCM

Our small molecule drug candidates, Rho kinase (ROCK) inhibitors, inhibit a downstream target of Rho. They have the potential to repair a broken blood brain barrier. They have been out-licensed to Neurelis for continued development.

ROCK is hyper-activated in endothelial cells in neurovascular disorders, including the disease of cerebral cavernous malformation (CCM), also called cavernous angioma, a serious genetic disease where endothelial lesions in the brain become leaky and bleed. There is no treatment for CCM except invasive surgery. ROCK is a target for treatment because the genetic mutation leading to angioma causes ROCK hyper-activation in brain capillary endothelial cells. Treatments effective for CCM also have utility in treating the blood brain defects in other neurovascular disorders, including stroke.

News

No. 6, 2024: Bioaxone BioSciences is pleased to announce the publication of article “The novel ROCK2 selective inhibitor NRL-1049 preserves the blood-brain barrier after acute injury” The preclinical data shows that NRL-1049 is a promising drug candidate to preserve the blood brain barrier after brain injury. Click here for a link to the publication.

July 5 2024: Dr. Lisa McKerracher has accepted an invitation to serve on the National Lab User Advisory Committee for the International Space Station (ISS). The ISS National Lab has a focus on space-based research to improve life on earth, including the advancement of biological research and neuroscience. The User Advisory committees recommends research priorities and provides assistance for ISS user community issues.

July 5 2024: BioAxone BioSciences Announces Patent Issued for Pharmaceutical Compositions of BA-210 for treatment of spinal cord injury Click here for the full story .

Events

Upcoming scientific conferences on spinal cord injury Click here to access site .

Information on cerebral cavernous malformation Click here to access site .



Address

90 Canal Street
4th Floor
Boston, MA 02114



Phone

617-401-3115